6134-61-8

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-furamide is used as a precursor for the synthesis of various pharmaceuticals due to its ability to be chemically modified to create a range of medicinal compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-bromo-2-furamide is utilized as a precursor in the production of agrochemicals, contributing to the development of pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Chemical Research and Development:
5-bromo-2-furamide is employed as a reagent in chemical research and development, where its versatile chemical properties are leveraged to explore new reactions and syntheses, leading to the discovery of novel compounds and materials.
Used as an Intermediate in Organic Compound Production:
5-bromo-2-furamide serves as an intermediate in the synthesis of other organic compounds, facilitating the creation of a diverse array of chemical entities for various applications across different industries.

InChI:InChI=1/C5H4BrNO2/c6-4-2-1-3(9-4)5(7)8/h1-2H,(H2,7,8)

Upstream product

• 26726-16-9 5-bromofuran-2-carbonyl chloride 
• 585-70-6 5-bromo-furan-2-carboxylic acid 

Downstream Products

• 57753-81-8 5-(4-chlorophenyl)furan-2-carboxamide 
• 1413063-98-5 acetic acid 2-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-6-(5-carbamoyl-furan-2-yl)-benzyl ester 
• 4915-06-4 5-bromofuran-2-carbonitrile 

Relevant academic research and scientific papers

Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor

The P2Y14 receptor (P2Y14R) mediates inflammatory activity by activating neutrophil motility, but few classes of antagonists are known. We have explored the structure-activity relationship of a 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-(aryl)benzoic acid antagonist scaffold, assisted by docking and molecular dynamics (MD) simulation at a P2Y14R homology model. A computational pipeline using the High Throughput MD Python environment guided the analogue design. Selection of candidates was based upon ligand-protein shape and complementarity and the persistence of ligand-protein interactions over time. Predictions of a favorable substitution of a 5-phenyl group with thiophene and an insertion of a three-methylene spacer between the 5-aromatic and alkyl amino moieties were largely consistent with empirical results. The substitution of a key carboxylate group on the core phenyl ring with tetrazole or truncation of the 5-aryl group reduced affinity. The most potent antagonists, using a fluorescent assay, were a primary 3-aminopropyl congener 20 (MRS4458) and phenyl p-carboxamide 30 (MRS4478).

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

T-BuXPhos: A highly efficient ligand for Buchwald-Hartwig coupling in water

An efficient and versatile 'green' catalytic system for the Buchwald-Hartwig cross-coupling reaction in water is reported. In an aqueous micellar medium, the combination of t-BuXPhos with [(cinnamyl)PdCl]2 showed excellent performance for coupling arylbromides or chlorides with a large set of amines, amides, ureas and carbamates. The method is functional-group tolerant, proceeds smoothly (30 to 50 °C) and provides rapid access to the target compounds in good to excellent isolated yields. When applied to the synthesis of a known NaV1.8 modulator, this method led to a significant improvement of the E-factor in comparison with classical organic synthesis. the Partner Organisations 2014.

BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP

The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.

BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP

The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.

New insertion reactions of some carbenoids into amide- and sulfonamide-NH bonds

In the presence of catalytic amounts of Rh2(OAc)4 in toluene, dimethyl diazomalonate (1) decomposed with evolution of N2 to form a carbenoid of type 8 which reacted with carboxamides 2 and toluenesulfonamide (4) to give 2-(acylamino)- and 2-(sulfonylamino)malonates 3 and 5, respectively. In an analogous reaction, α-diazo ketone 6 and 4 yielded N-(2-oxo-1,2-diphenylethyl)toluenesulfonamide (7).

Chemistry of furans: Part VIII - Synthesis of 5-dialkylamino-2-furanamides and furanopeptides

The synthesis of 5-dialkylamino-furanamides by the nucleophilic displacement of bromine on 5-bromo-2-furanamides with pyrrolidine, piperidine and morpholine is described.Several other primary and secondary amines as well as nucleophiles such as sodio amid

Chemistry of Furans: Part VI - Synthesis of 5-Amino-2-furanamides

5-Amino-2-furanamides (II) have been synthesised by the nucleophilic displacement of bromine in 5-bromo-2-furanamides by piperidine, pyrrolidine and morpholine.

Hypoglycemic 5-substituted oxazolidine-2,4-diones

Hypoglycemic 5-furyl and 5-thienyl derivatives of oxazolidine-2,4-dione and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; and intermediates useful in the preparation of said compounds.